The monospecific enediyne-energized fusion proteins EGF-LDP-AE and LDP-IGF-AE (at 0.4 mg/kg) demonstrated similar antitumor activity (67.6% and 72% tumor growth inhibition, respectively, p > 0.05) to the bispecific fusion protein EGF-IGF-LDP-AE when given at 0.2 mg/kg. This evidence concerns the gene CPQ and neoplasm.